🚨Trade Alert 🚨 CMND

This little-known psychedelic company may have a superior solution to a growing problem.  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ This little-known psychedelic company may have a superior solution to a growing problem. Greetings All, There is a lot of excitement surrounding psychedelics on Wall Street. In fact, Wall Street is [betting tens of millions of dollars]( on psychedelic drugs that backers say could treat mental illness for a fraction of what it costs to do therapy with better-known treatments!” Did you know that psychedelics are even being looked at as a way to treat alcohol use disorder? America’s alcohol problem is an overlooked and deadly epidemic. The acceptance of alcohol in America is widely known, but it has caused a tremendously unhealthy relationship for many of its users. More than 6 percent of adults in the U.S. have an [alcohol use disorder]( about 1 in 12 men and 1 in 25 women. An additional 623,000 people between the ages of 12 and 17 have alcohol use disorders. About 88,000 people die of alcohol-related causes every year in the United States. A newer study found that two doses of psilocybin, a compound found in psychedelic mushrooms, had reduced heavy drinking by a whopping 83% on average among heavy drinkers when combined with psychotherapy. You can read more about this study [HERE.]( All of this puts one emerging NASDAQ company into the spotlight that is trading currently at only PENNIES! Clearmind Medicines, Inc. (NASDAQ: CMND) is a little-known biotech company that focuses on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems. One of these health problems is alcohol use disorder. In the last week, shares have moved from around 39 cents to over 45 cents for a breakout of over 15%! This momentum may continue as more of Wall Street discovers CMND and what this biotech is remarkably doing with its psychedelic-derived therapeutics. This is an excellent time to be paying attention to CMND for several reasons: First, let’s look at the booming psychedelics space. - The global market for psychedelic therapeutics is expected to more than double to [$8 billion by 2029.]( - Twenty-five states have considered legislation to make psychedelics available for therapeutic use, and the FDA is expected to approve substances like MDMA or psilocybin for mental health treatment within the next few years. - As time goes by, consumers may express more willingness to consider the therapeutic effects of hallucinogens, which in turn will create a tremendous market. - Psychedelic stocks have a bright future with[13.5%]( compound annual growth expected through 2029! Now, let’s look at what CMND has going on: - The company’s intellectual portfolio currently consists of an impressive fourteen patent families. - The company has chosen its first U.S. site for the company’s Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 compound for the treatment of alcohol use disorder ("AUD"). - CMND-100 has the potential to be a game-changer in treating addictions and mental health concerns. - The company has an ongoing collaboration with SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, it has entered into a research agreement with the Hebrew University of Jerusalem, to evaluate Clearmind's and SciSparc's combination treatment for obesity and metabolic syndrome. - The company has filed a provisional patent application for the treatment of Dyskinesia with the United States Patent and Trademark Office (“USPTO”), as part of its overarching strategy to further strengthen its robust IP portfolio. The patent application refers to the psychedelic molecule 3-Methylmethcathinone ("3-MMC”) as a potential treatment for Dyskinesia thus expanding Clearmind’s IP portfolio for innovative molecules, new indications and treatments. Decades ago, psychedelics were considered a countercultural fad. Today they are being looked at as mainstream medicine. As the conversation about psychedelics heats up, Clearmind Medicines, Inc. (NASDAQ: CMND) should be on your radar as it tackles several lucrative disorders in the healthcare arena. [( Company Overview: Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. A New Psychoactive Molecule Called MEAI: Breaking the Addiction Cycle MEAI holds the promise to break the vicious binge-drinking cycle by potentially innervating neural pathways such as 5-HT1A, which leads to decreased impulsivity and “sensible behavior”. Self-Administered & Limiting Pre-clinical in vivo results demonstrate longtail tapering off of activity via oral administration. This may explain the self-limiting property of MEAI — unlike traditional treatments. Widely Applicable The literature shows that 5-HT1A receptors are associated with controlling craving behavior across the board. This indicates that MEAI may have a wide range of applications beyond binge drinking. How does it work? MEAI exerts a euphoric alcohol-like experience and a reduced desire to consume alcoholic beverages with potential to change the lives of millions who struggle to drink in moderation! To see how MEAI works in action, check out this YouTube video where Mark Haden, CMND’s VP Business Development, describes the MEAI treatment experience: [ may be a revolutionary way to treat alcohol abuse disorder and could change the lives of millions of people who suffer from the disorder. CMND’s first indication is alcohol use disorder, and it affects millions of Americans. - Over 57 million Americans report four or more episodes of heavy drinking per month, with an average of seven drinks per episode. (1) - Over 18 million Americans struggle with Alcohol Use Disorder (2), which is the inability to reduce alcohol consumption. - 55% of victims of intimate partner violence report alcohol abuse by their abuse partner. (3) - Approximately half of all sexual assaults are committed by men who had been drinking alcohol. (4) - 35% of parental child abuse offenders consumed either alcohol or drugs at the time of the incident. (5) [[1] Annual Total Binge Drinks Consumed by U.S. Adults, 2015. Am J Prev Med. 2018 Apr;54(4):486-496]( [[2] Key Substance Use and Mental Health Indicators in the United States: Results from the 2017 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration, September 14, 2018]( [[3] Alcohol and Crime: An Analysis of National Data on the Prevalence of Alcohol Involvement in Crime, U.S. Department of Justice, 1998]( Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder… It was in May of 2023 that CMND announced the selection of its first U.S. site for the company’s Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 compound for the treatment of alcohol use disorder ("AUD"). Yale School of Medicine’s Department of Psychiatry is the first US-based clinical site to join the company's first-in-human (FIH) trial. The site will be led by Anahita Bassir Nia, MD, a specialist in substance abuse, including alcohol abuse. “We are honored to have Yale School of Medicine’s Department of Psychiatry as part of our clinical trial," said Clearmind’s Chief Executive Officer Dr. Adi Zuloff-Shani. “We see this collaboration with a global pioneer in psychedelics research, as further validation of our innovative drug candidate for potential treatment for alcohol use disorder.” Clearmind has also been granted approval by the Ethics Committee (equivalent of an institutional review board) of Israel’s IMCA center for thePhase I/IIa clinical trial of CMND-100. The CM-CMND-001 clinical trial is a multinational, multi-center, Phase I/II single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects. “We believe that CMND-100 has the potential to be a game-changer in treating addictions and mental health concerns, as successfully demonstrated in previous pre-clinical studies,” added Dr. Zuloff-Shani. “With an extensive IP portfolio and an award-winning advisory board of renowned psychiatrists and researchers from around the world, we’re confident in our unique treatment model. CMND-100 is expected to provide immediate therapeutic benefit, as a self-administered and non-addictive prescription pill that is not dependent on expensive therapies." In the clinical trial, oral capsules will be administered once daily for ten consecutive days. The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period. The primary end-point of the trial is to find the tolerable dose and characterize the safety and pharmacokinetics/ pharmacodynamics (PK/PD) of single and repeated doses of CMND-100 in healthy subjects and in those with AUD. The secondary end-point is to evaluate the efficacy of CMND-100 in reduction of drinking patterns and craving in individuals with moderate-to-severe AUD. Obesity and Metabolic Syndrome: CMND has filed a provision patent applicated related to metabolic syndromes including obesity. “We are excited to further investigate the effect of the combination of MEAI and PEA for treating obesity and metabolic syndrome. Previous pre-clinical studies performed with our proprietary MEAI showed a very positive effect in treating obesity. In this study we want to further investigate the synergistic effect between our MEAI and SciSparc’ s PEA," said Clearmind’s Chief Executive Officer, Dr. Adi Zuloff-Shani. "The collaboration with SciSparc has already yielded numerous patent applications related to combination therapies for treating binge behaviors, cocaine addiction, depression and more." The upcoming study will evaluate the effect of the combination of MEAI and PEA on food intake, metabolic and activity profiles. Watch for developments on this! In Summary… From counterculture to therapy, psychedelics have come a long way and it looks like they are now here to stay. The industry is still in its infancy, but many are anticipating it will grow to be something quite remarkable. Many also anticipate that psychedelics will be the future treatment for things like addiction and mental health issues. CMND continues to strengthen its position as a leader in the psychedelic-derived therapeutics industry through an aggressive strategy to expand its IP portfolio. At current levels, the company may be at a supreme value as it tackles big markets which include alcohol use disorder… a problem that America desperately needs to address. Shares of CMND have been on an upward climb and this could be just the beginning of bigger things to come. Start your own research! Copyright 2023 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in CMND. We have been currently compensated up to Twenty Five Thousand Dollars Cash ($25,000) via bank wire transfer from a third-party IA Media, LLC for a 1 Day Marketing Program regarding CMND with a start date of 9/06/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Small Caps Daily 1334 Northampton St Easton, PA 18042 © 2023 | All rights reserved. [Unsubscribe](. [Twitter] [Facebook] [Instagram]